• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Aurora Cannabis Inc.

    9/20/24 4:12:04 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $ACB alert in real time by email
    S-8 1 d804816ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on September 20, 2024

    Registration No. 333-    

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    AURORA CANNABIS INC.

    (Exact name of Registrant as specified in its charter)

     

     

     

    British Columbia, Canada   Not Applicable

    (State or other jurisdiction of

    incorporation or organization)

     

    (IRS Employer

    Identification No.)

    2207 90B St. SW

    Edmonton, Alberta

    T6X 1V8

    Canada

    Tel: (855) 279-4652

    (Address, including zip code, of Registrant’s principal executive offices)

    Share Option Plan

    Non-Employee Directors Deferred Share Unit Plan

    Performance Share Unit Plan

    Restricted Share Unit Plan

    (Full title of the plans)

    PUGLISI & ASSOCIATES

    850 Library Avenue

    Suite 204

    Newark, DE 19711

    (302) 738-6680

    (Telephone number, including area code, of agent for service)

     

     

    COPIES TO:

     

    Nathalie Clark

    Aurora Cannabis Inc.

    2207 90B St. SW

    Edmonton, Alberta

    T6X 1V8

    Canada

    Tel: (855) 279-4652

     

    Adam M. Givertz

    Paul, Weiss, Rifkind, Wharton & Garrison LLP

    1285 Avenue of the Americas

    New York, NY

    10019

    Tel: (212) 373-3000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☒
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1.

    Plan Information.

    The documents containing the information specified in Part I of Form S-8 will be sent or given to participants in each of the Share Option Plan, Non-Employee Directors Deferred Share Unit Plan, Performance Share Unit Plan and Restricted Share Unit Plan of Aurora Cannabis Inc. (the “Registrant”), as specified by Rule 428(b)(1) under the U.S. Securities Act of 1933, as amended (the “Securities Act”). In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission, but each such document constitutes, along with the documents incorporated by reference into this Registration Statement, a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

    Item 2.

    Registrant Information and Employee Plan Annual Information.

    The Registrant will furnish without charge to each person to whom a prospectus is delivered, upon the written or oral request of such person, a copy of any and all of the documents incorporated by reference in Item 3 of Part II of this Registration Statement, other than exhibits to such documents (unless such exhibits are specifically incorporated by reference to the information that is incorporated). Those documents are incorporated by reference in each Section 10(a) prospectus. The Registrant will also furnish without charge to any person to whom a prospectus is delivered, upon written or oral request, all other documents required to be delivered pursuant to Rule 428(b) under the Securities Act. Requests should be directed to the General Counsel & Corporate Secretary of Aurora Cannabis Inc. at 2207 90B St. SW, Edmonton, Alberta, Canada T6X 1V8, telephone: (855) 279-4652.


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

    The following documents filed with or furnished to the Commission are incorporated herein by reference:

    1. The Registrant’s annual report on Form 40-F filed with the Commission on June 20, 2024 (Commission File No. 001-38691).

    2. The Registrant’s reports on Form 6-K furnished to the Commission on July 5, 2024, July 9, 2024, July  26, 2024, August 6, 2024, August 7, 2024, August 12, 2024, August  26, 2024, September 17, 2024 and September 20, 2024.

    3. The description of the common shares of the Registrant contained under the section captioned “Item 1. Description of Registrant’s Securities to be Registered” in the Registrant’s Registration Statement on Form 8-A filed with the Commission on May 24, 2021 (Commission File No. 001-38691), including any amendment or report filed for the purpose of amending such description.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part thereof from the date of filing of such documents. Also, the Registrant may incorporate by reference its future reports on Form 6-K by stating in those Form 6-Ks that they are being incorporated by reference into this Registration Statement.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4.

    Description of Securities.

    Not Applicable.

     

    Item 5.

    Interests of Named Experts and Counsel.

    Not Applicable.

     

    Item 6.

    Indemnification of Directors and Officers.

    Aurora Cannabis Inc. (“we”, “us” or “our company”) is subject to the provisions of Part 5, Division 5 of the Business Corporations Act (British Columbia) (the “Act”).

    Under Section 160 of the Act, we may, subject to Section 163 of the Act:

    (a) indemnify an individual who:

    (i) is or was a director or officer of our company,

    (ii) is or was a director or officer of another corporation (A) at a time when such corporation is or was an affiliate of our company; or (B) at our request, or

    (iii) at our request, is or was, or holds or held a position equivalent to that of, a director or officer of a partnership, trust, joint venture or other unincorporated entity,


    including, subject to certain limited exceptions, the heirs and personal or other legal representatives of that individual (collectively, an “eligible party”), against all eligible penalties, defined below, to which the eligible party is or may be liable; and

    (b) after final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an eligible party in respect of that proceeding, where:

    (i) “eligible penalty” means a judgment, penalty or fine awarded or imposed in, or an amount paid in settlement of, an eligible proceeding,

    (ii) “eligible proceeding” means a proceeding in which an eligible party or any of the heirs and personal or other legal representatives of the eligible party, by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, our company or an associated corporation (A) is or may be joined as a party, or (B) is or may be liable for or in respect of a judgment, penalty or fine in, or expenses related to, the proceeding,

    (iii) “expenses” includes costs, charges and expenses, including legal and other fees, but does not include judgments, penalties, fines or amounts paid in settlement of a proceeding, and

    (iv) “proceeding” includes any legal proceeding or investigative action, whether current, threatened, pending or completed.

    Under Section 161 of the Act, and subject to Section 163 of the Act, we must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by an eligible party in respect of that proceeding if the eligible party (a) has not been reimbursed for those expenses, and (b) is wholly successful, on the merits or otherwise, in the outcome of the proceeding or is substantially successful on the merits in the outcome of the proceeding.

    Under Section 162 of the Act, and subject to Section 163 of the Act, we may pay, as they are incurred in advance of the final disposition of an eligible proceeding, the expenses actually and reasonably incurred by an eligible party in respect of the proceeding, provided that we must not make such payments unless we first receive from the eligible party a written undertaking that, if it is ultimately determined that the payment of expenses is prohibited under Section 163 of the Act, the eligible party will repay the amounts advanced.

    Under Section 163 of the Act, we must not indemnify an eligible party against eligible penalties to which the eligible party is or may be liable or pay the expenses of an eligible party in respect of that proceeding under Sections 160, 161 or 162 of the Act, as the case may be, if any of the following circumstances apply:

    (a) if the indemnity or payment is made under an earlier agreement to indemnify or pay expenses and, at the time that the agreement to indemnify or pay expenses was made, we were prohibited from giving the indemnity or paying the expenses by our memorandum or articles;

    (b) if the indemnity or payment is made otherwise than under an earlier agreement to indemnify or pay expenses and, at the time that the indemnity or payment is made, we are prohibited from giving the indemnity or paying the expenses by our memorandum or articles;

    (c) if, in relation to the subject matter of the eligible proceeding, the eligible party did not act honestly and in good faith with a view to the best interests of our company or the associated corporation, as the case may be; or

    (d) in the case of an eligible proceeding other than a civil proceeding, if the eligible party did not have reasonable grounds for believing that the eligible party’s conduct in respect of which the proceeding was brought was lawful.

    If an eligible proceeding is brought against an eligible party by or on behalf of our company or by or on behalf of an associated corporation, we must not either indemnify the eligible party against eligible penalties to which the eligible party is or may be liable, or pay the expenses of the eligible party under Sections 160, 161 or 162 of the Act, as the case may be, in respect of the proceeding.


    Under Section 164 of the Act, and despite any other provision of Part 5, Division 5 of the Act and whether or not payment of expenses or indemnification has been sought, authorized or declined under Part 5, Division 5 of the Act, on application of our company or an eligible party, the court may do one or more of the following:

    (a) order us to indemnify an eligible party against any liability incurred by the eligible party in respect of an eligible proceeding;

    (b) order us to pay some or all of the expenses incurred by an eligible party in respect of an eligible proceeding;

    (c) order the enforcement of, or any payment under, an agreement of indemnification entered into by us;

    (d) order us to pay some or all of the expenses actually and reasonably incurred by any person in obtaining an order under Section 164 of the Act; or

    (e) make any other order the court considers appropriate.

    Section 165 of the Act provides that we may purchase and maintain insurance for the benefit of an eligible party or the heirs and personal or other legal representatives of the eligible party against any liability that may be incurred by reason of the eligible party being or having been a director or officer of, or holding or having held a position equivalent to that of a director or officer of, our company or an associated corporation.

    Under Part 21.2 of our articles, and subject to the Act, we must indemnify an eligible party and his or her heirs and legal personal representatives against all eligible penalties to which such person is or may be liable, and we must, after the final disposition of an eligible proceeding, pay the expenses actually and reasonably incurred by such person in respect of that proceeding. Each eligible party is deemed to have contracted with our company on the terms of the indemnity contained in our articles.

    Under Part 21.3 of our articles, and subject to the Act, we may agree to indemnify and may indemnify any person (including an eligible party) against eligible penalties and pay expenses incurred in connection with the performance of services by that person for our company. We have entered into indemnity agreements with certain of our directors and officers.

    Under Part 21.4 of our articles, we may advance expenses to an eligible party to the extent permitted by and in accordance with the Act.

    Pursuant to Part 21.5 of our articles, the failure of an eligible party of our company to comply with the Act, our articles or, if applicable, any former Companies Act or former articles does not, of itself, invalidate any indemnity to which he or she is entitled under our articles.

    Under Part 21.6 of our articles, we may purchase and maintain insurance for the benefit of any eligible party (or his or her heirs or legal personal representatives of any eligible party) against any liability incurred by any eligible party.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, we have been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Act and is therefore unenforceable.

     

    Item 7.

    Exemption from Registration Claimed.

    Not Applicable.

     

    Item 8.

    Exhibits.

    The exhibits listed under the caption “Exhibits Index” of this Registration Statement are incorporated by reference herein.


    Item 9.

    Undertakings.

    The Registrant hereby undertakes:

    (a)(1) To file during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that, paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement;

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered hereby which remain unsold at the termination of the offering.

    (b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering hereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    INDEX TO EXHIBITS

     

    4.1   

    Articles of the Registrant, as Amended.

    4.2   

    Share Option Plan.

    4.3   

    Non-Employee Directors Deferred Share Unit Plan.

    4.4   

    Performance Share Unit Plan.

    4.5   

    Restricted Share Unit Plan.

    5.1   

    Opinion of Stikeman Elliott LLP.

    23.1   

    Consent of KPMG LLP.

    23.2   

    Consent of Stikeman Elliott LLP (included in Exhibit  5.1 to this Registration Statement).

    24.1   

    Powers of Attorney (included on signature pages of this Part II).

    107   

    Filing Fee Table.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Edmonton, Alberta, Canada, on the 20th day of September, 2024.

     

    AURORA CANNABIS INC.
    By:   /s/ Simona King
     

    Name: Simona King

    Title:  Chief Financial Officer


    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Miguel Martin, Simona King and Nathalie Clark, or any of them, his or her true and lawful attorneys-in-fact and agents, each of whom may act alone, with full powers of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments to this Registration Statement, including post-effective amendments to this Registration Statement and registration statements filed pursuant to Rule 429 under the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and other documents and in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all his or her said attorneys-in-fact and agents or any of them or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    This Power of Attorney may be executed in multiple counterparts, each of which shall be deemed an original, but which taken together shall constitute one instrument.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Miguel Martin

    Miguel Martin

      

    Chief Executive Officer and Executive Chairman

    (Principal Executive Officer)

      September 20, 2024

    /s/ Simona King

    Simona King

      

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

      September 20, 2024

    /s/ Ronald Funk

    Ronald Funk

      

    Lead Independent Director

      September 20, 2024

    /s/ Norma Beauchamp

    Norma Beauchamp

      

    Director

      September 20, 2024

    /s/ Theresa Firestone

    Theresa Firestone

      

    Director

      September 20, 2024

    /s/ Chitwant Kohli

    Chitwant Kohli

      

    Director

      September 20, 2024

    /s/ Michael Singer

    Michael Singer

      

    Director

      September 20, 2024

    /s/ Rajesh Uttamchandani

    Rajesh Uttamchandani

      

    Director

      September 20, 2024


    AUTHORIZED REPRESENTATIVE

    Pursuant to the requirements of Section 6(a) of the Securities Act of 1933, as amended, the undersigned has signed this Registration Statement, solely in the capacity of the duly authorized representative of Aurora Cannabis Inc. in the United States, on the 20th day of September, 2024.

     

    PUGLISI & ASSOCIATES

    Authorized representative in the United States

    By:   /s/ Donald J. Puglisi
     

    Name: Donald J. Puglisi

    Title:  Managing Director

    Get the next $ACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Canaccord Genuity
    12/11/2024Buy
    TD Cowen
    2/9/2024Hold → Buy
    Canaccord Genuity
    9/21/2022Sell → Hold
    Canaccord Genuity
    6/24/2022Neutral → Overweight
    Cantor Fitzgerald
    6/6/2022Sell → Hold
    Stifel
    11/10/2021$9.60 → $10.75Neutral
    Cantor Fitzgerald
    10/28/2021$9.50 → $9.60Neutral
    Cantor Fitzgerald
    More analyst ratings

    $ACB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand

    NASDAQ | TSX: ACB Launch reinforces Aurora's leadership position across key international markets  EDMONTON, AB, Feb. 11, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, is expanding its Aurora® medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth.

    2/11/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program

    NASDAQ | TSX: ACB EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has filed a prospectus supplement establishing a new at-the-market offering program (the "ATM Program") that allows the Company to issue and sell up to U.S.$100 million of common shares in the capital of the Company (the "Common Shares") from treasury to the public, from time to time, at the Company's discretion. The Company intends to use the net proceeds from th

    2/4/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis Announces Fiscal 2026 Third Quarter Results

    NASDAQ | TSX: ACB Expands YoY Total Net Revenue1 by 7% to $94.2 million, with Global Medical Cannabis Net Revenue1 Increasing by 12% to a Record $76.2 millionDelivers Adjusted EBITDA1 of $18.5 million and Adjusted Net Income1 of $7.2 millionGenerates Free Cash Flow1 of $15.5 million Maintains Strong Balance Sheet with $154.4 million of Cash2 and Short-Term Investments, and a Debt-Free Cannabis Business2EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025.

    2/4/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    SEC Filings

    View All

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    2/4/26 4:44:28 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    2/4/26 9:45:22 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Aurora Cannabis Inc.

    6-K - AURORA CANNABIS INC (0001683541) (Filer)

    2/4/26 7:27:19 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Aurora Cannabis

    Canaccord Genuity initiated coverage of Aurora Cannabis with a rating of Buy

    1/27/26 9:29:20 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    TD Cowen initiated coverage on Aurora Cannabis

    TD Cowen initiated coverage of Aurora Cannabis with a rating of Buy

    12/11/24 10:35:16 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Aurora Cannabis from Hold to Buy

    2/9/24 6:09:16 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Leadership Updates

    Live Leadership Updates

    View All

    Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand

    NASDAQ | TSX: ACB EDMONTON, AB, Dec. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driving growth in these key markets, drawing on decades of global experience in fast moving, regulated industries. "I'm excited to join Aurora at an inflection point in the company's global leadership and to work alongside a team dedicated

    12/8/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Announces Distribution Partnership with Leafio Australia

    The collaboration will improve medical cannabis access and better serve patients across Australia NASDAQ | TSX: ACB EDMONTON, AB, Dec. 2, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, today announced the company's wholly owned subsidiary, MedReleaf Australia, has entered into a distribution partnership with Leafio, the wholesale distribution arm of Montu Australia. This strategic partnership will expand patient access to trusted, safe, and effective medical cannabis across Australia, while supporting healthcare professionals with educational resources. Leafio will serve as a wholesaler of Aurora's leading portfoli

    12/2/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Rubicon Organics Announces Appointment of Glen Ibbott as CFO

    VANCOUVER, British Columbia, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV:ROMJ) (OTCQX:ROMJF) ("Rubicon Organics", "Rubicon", or the "Company"), a licensed producer focused on cultivating and selling organic certified and premium cannabis products, today announced the appointment of Glen Ibbott, a cannabis industry veteran and former Chief Financial Officer of Aurora Cannabis Inc. (TSX:ACB, NASDAQ:ACB) as its Chief Financial Officer and Corporate Secretary. "Over the past six months, Glen has demonstrated exceptional leadership, deep industry expertise, and a strong alignment with our values. His strategic insight and financial acumen have already made a significant impac

    11/12/25 8:00:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Financials

    Live finance-specific insights

    View All

    Aurora Cannabis Announces Fiscal 2026 Third Quarter Results

    NASDAQ | TSX: ACB Expands YoY Total Net Revenue1 by 7% to $94.2 million, with Global Medical Cannabis Net Revenue1 Increasing by 12% to a Record $76.2 millionDelivers Adjusted EBITDA1 of $18.5 million and Adjusted Net Income1 of $7.2 millionGenerates Free Cash Flow1 of $15.5 million Maintains Strong Balance Sheet with $154.4 million of Cash2 and Short-Term Investments, and a Debt-Free Cannabis Business2EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025.

    2/4/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis to Host Third Quarter 2026 Investor Conference Call

    NASDAQ | TSX: ACB EDMONTON, AB, Jan. 21, 2026 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), the Canadian based leading global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its third quarter 2026 on Wednesday, February 4, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the third quarter 2026 before the opening of markets that same day. Conference Call Details DATE: Wednesday, February 4, 2026 TIME: 8:00 a.m. Eastern Time |

    1/21/26 4:35:00 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Aurora Cannabis Announces Fiscal 2026 Second Quarter Results

    Expands YoY Global Medical Cannabis Net Revenue1 by 15% to Record $70.5 millionIncreases International Medical Cannabis Net Revenue1 by 22% to Record $42.7 million, with leadership positions across key marketsDelivers Adjusted EBITDA1 growth of 52%, reaching $15.4 million  Maintains Strong Balance Sheet with $141.9 million of Cash and Debt-Free Cannabis Business2NASDAQ | TSX: ACB EDMONTON, AB, Nov. 5, 2025 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025.

    11/5/25 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

    SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

    2/14/23 11:28:04 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Aurora Cannabis Inc.

    SC 13G - AURORA CANNABIS INC (0001683541) (Subject)

    6/1/22 10:14:29 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Aurora Cannabis Inc. (Amendment)

    SC 13G/A - AURORA CANNABIS INC (0001683541) (Subject)

    2/14/22 3:54:29 PM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care